First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer, Coupled to Extensive Translational Studies
Latest Information Update: 22 Jun 2024
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms FIOL
- 06 May 2024 Planned End Date changed from 31 Aug 2023 to 31 Dec 2025.
- 06 May 2024 Planned primary completion date changed from 31 Aug 2023 to 1 Jun 2025.
- 11 Apr 2024 This trial has been completed in Denmark (End Date: 1 Jul 2021), according to European Clinical Trials Database record.